Study finds long COVID can make MG symptoms worse
A study tracked MG patients for 12 months after COVID-19 to examine how lingering symptoms related to disease exacerbations.
News
-
-
MG diagnosis often delayed, especially for minority patients
Patients with generalized myasthenia gravis (gMG) often face long waits of up to 26 months before getting the right diagnosis.
-
MG rates increasing among older US population
The incidence (number of new cases) and prevalence (sum of old and new cases) of MG appears to be rising among U.S. seniors.
-
Study finds patients with seronegative MG less likely to have exacerbations
Double-seronegativity in MG is protective against exacerbations in patients who have achieved minimal manifestation or better status.
-
New review highlights often-missed symptoms of MG
Nonmotor symptoms including depression, memory problems, gastrointestinal issues and cardiovascular abnormalities can affect people with MG.
-
Vascular diseases a significant cause of mortality in patients with MG
Vascular and respiratory diseases contribute significantly to MG-associated deaths.
-
Single dose of efgartigimod helps MG patients before thymectomy
A single presurgery dose of efgartigimod can be a helpful temporary treatment for MG patients waiting for a thymectomy.
-
New research suggests long-term benefits of rituximab for new-onset MG
Rituximab offers a promising option for managing MG. However, further research is needed to fully assess its long-term benefit-risk profile.
-
Early thymectomy improves remission in ocular myasthenia gravis
Patients with ocular myasthenia gravis who undergo thymectomy before generalization are more likely to achieve lasting remission.
-
New data indicates inebilizumab improves quality of life in MG
A monoclonal antibody used to treat two rare autoimmune diseases improved quality-of-life in patients diagnosed with generalized MG.
